What Researchers Did
Researchers retrospectively analyzed the outcomes of combining 131I-meta-iodobenzylguanidine (MIBG) with hyperbaric oxygen therapy (HBOT) in high-risk neuroblastoma patients.
What They Found
Out of seven high-risk relapsed neuroblastoma patients, three (43%) survived with no evidence of disease, while four (57%) died due to disease progression. The combined treatment, which included 14 administrations of 131I-MIBG followed by four days of hyperbaric oxygen therapy per administration, was generally well tolerated, with acute and late side effects rarely exceeding grade 3 or 4.
What This Means for Canadian Patients
For Canadian children facing high-risk or relapsed neuroblastoma, this study suggests that a combined therapy involving 131I-MIBG and hyperbaric oxygen could be a tolerable option that may improve survival for some. While further research is needed, it offers a potential avenue for treatment where current options are often limited.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This was a small, retrospective study with only seven patients, limiting the generalizability and strength of its conclusions.